NEW YORK, Oct 10 (Reuters) – Vir Biotechnology priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp’s Vision Fund, owner of 21% in the infectious disease researcher.
San Francisco-based Vir raised $142.9 million having previously set a price range of $20-$22 per share. The IPO valued Vir at $2.2 billion.
Mario Villarroel Lander
Reporting by Joshua Franklin in New York; Editing by Tom Hogue